Success stories

SARISA Therapeutics 

Dr. Shengmin Sang 

Learn more about Dr. Sang

Patients who require the benefits of aspirin without the accompanying stomach irritation are a step closer to comfort and cures with the signing of an exclusive licensing agreement. Dr. Shengmin Sang, a food scientist with North Carolina Agricultural and Technical State University, licensed his patent for a family of novel aspirin-derived compounds to SARISA Therapeutics, an Invenshure Company out of Minneapolis, Minn. Sang’s patented compounds may be useful in treating or preventing colon cancer, heart disease and other disorders. Through this commercialization effort, more patients may be able to receive the benefits of aspirin without incurring adverse side effects.

In April 2017, the U.S. Preventive Services Task Force added colon cancer to the list of diseases for which aspirin should be prescribed as a preventive treatment. SARISA Therapeutics aims to make Dr. Sang’s discoveries available to all patients who need aspirin’s therapeutic usefulness minus its gastric irritation side effects.

Triad Growth Partners 

Dr. Stephanie Luster-Teasley 

Learn more about Dr. Luster-Teasley 

Dr. Stephanie Luster-Teasley is an associate professor and chair of the Department of Civil, Architectural and Environmental Engineering at N.C. A&T. Her research involves chemical oxidation, water and wastewater treatment and remediation. Her patented RemRx™ treatment technology supports the sustainability efforts of Triad Growth Partners in Greensboro, North Carolina.

Triad Growth Partners is developing innovative solutions for the $60 billion remediation market to decrease cost, increase efficacy and restore water and land in a sustainable manner. AxNano (the technology development group of Triad Growth Partners) is designing these advanced solutions as part of Luster-Teasley’s RemRx treatment technologies platform. RemRx brings together advanced technologies to create proprietary and highly tunable products that safely address the needs of global development leaders and industry looking for sustainable solutions.


Dr. Salil Desai 

Learn more about Dr. Desai

Micro- and nano scale printing is getting more efficient thanks to a new technology invented by Dr. Salil Desai, a professor in the Department of Industrial and Systems Engineering at N.C. A&T. His invention changes the physical form of droplets exiting a printhead by dramatically reducing their size before their controlled deposition on a flat, curved or flexible substrate. This dramatic level of control maintains the advantages of Emb3Ded’s non-contact printing for use in electronic, biological, and optical manufacturing where contamination is of concern.

Emb3Ded, is an additive manufacturing company with initial focus on biotechnology utilizing 3-D bioprinting. Emb3Ded combines Desai’s patented process and apparatus with multiple additive manufacturing technologies to produce materials and cells that mimic the natural shape of tissues in the human body. Emb3Ded’s products and services are in demand for the biomedical, Regenerative and precision medicine industries.